A topical, fixed-dose combination therapy primarily indicated for the treatment of androgenetic alopecia (male and female pattern hair loss). It combines a vasodilator (Minoxidil) to stimulate hair growth, a retinoid (Tretinoin) to enhance follicular penetration and cellular proliferation, and a low-potency corticosteroid (Hydrocortisone) to mitigate potential local irritation and inflammation. This combination is considered a second-line or adjunctive therapy in resistant cases.
Adult: Apply 1 mL of the solution twice daily (morning and evening) to the dry scalp in the affected area. Total daily dose should not exceed 2 mL.
Note: 1. Apply to clean, completely dry scalp. 2. Part hair to expose affected area. 3. Use the applicator to apply solution directly to the scalp, not the hair. 4. Gently massage with fingertips. 5. Wash hands thoroughly after application. 6. Allow solution to dry for at least 4 hours before washing hair, wearing hats, or going to bed. Do not use a hairdryer to dry the solution.
The combination works synergistically. Minoxidil sulfate opens potassium channels, causing hyperpolarization of vascular smooth muscle cells, leading to vasodilation and increased blood flow to hair follicles. It also prolongs the anagen (growth) phase. Tretinoin enhances epidermal penetration of Minoxidil, upregulates follicular sulfotransferase activity (increasing conversion to active minoxidil sulfate), and modulates keratinocyte differentiation and proliferation. Hydrocortisone provides anti-inflammatory and immunosuppressive effects, reducing perifollicular inflammation seen in some alopecias and mitigating irritation caused by Tretinoin.
Pregnancy: CONTRANDICATED. Tretinoin is teratogenic (Pregnancy Category D as per some references, Category C for topical). Minoxidil is Pregnancy Category C. Risk of fetal harm outweighs any benefit. Women of childbearing potential must use effective contraception.
Driving: Generally safe. However, if systemic absorption causes dizziness or lightheadedness, patients should not drive or operate machinery until they know how the medication affects them.
| Topical Corticosteroids (Potent) | Increased risk of skin atrophy, telangiectasia, and systemic absorption of steroids. | Major |
| Topical Retinoids (e.g., Adapalene) or Keratolytics (e.g., Salicylic Acid) | Severe local irritation, dryness, and dermatitis. | Major |
| Antihypertensives (especially Guanethidine) | Potentiation of hypotensive effects; risk of severe hypotension. | Major |
| Systemic Corticosteroids | Additive risk of hypothalamic-pituitary-adrenal (HPA) axis suppression. | Moderate |
| Photosensitizing Drugs (e.g., Tetracyclines, Fluoroquinolones) | Increased risk of photosensitivity reaction due to Tretinoin. | Moderate |
Same composition (Hydrocortisone (0.01% w/v) + Minoxidil (5% w/v) + Tretinoin (0.025% w/v)), different brands: